GlaxoSmithKline Responds to FDA on Cervarix and Plans to Submit Final Study Data for Approval

GlaxoSmithKline today provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer.

The whole story can be read here.